Last reviewed · How we verify

NCT06094712

A Study to Evaluate the Pharmacokinetics of the CORT125134 Phase 2 Formulation in Healthy Male Subjects

Completed Phase 1 Last updated 23 October 2023
What this trial tests

Phase 1 trial testing CORT125134 in Healthy in 8 participants. Completed in 27 April 2016.

Timeline
7 April 2016
Primary endpoint
27 April 2016
27 April 2016

Quick facts

Lead sponsorCorcept Therapeutics
PhasePhase 1
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposeother
Enrollment8
Start date7 April 2016
Primary completion27 April 2016
Estimated completion27 April 2016
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Corcept Therapeutics — full company profile →

Who can join

Adults 18 to 55, male only, with Healthy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A study designed to characterize the pharmacokinetic (PK) profile of CORT125134 following a single 150-mg oral dose of the Phase 2 capsule formulation of CORT125134 in 8 healthy male subjects.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Healthy

Currently open trials in the same condition.

Other Corcept Therapeutics trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06094712.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing